AR130506A1 - Anticuerpos anti-lair1 humano - Google Patents
Anticuerpos anti-lair1 humanoInfo
- Publication number
- AR130506A1 AR130506A1 ARP230102472A ARP230102472A AR130506A1 AR 130506 A1 AR130506 A1 AR 130506A1 AR P230102472 A ARP230102472 A AR P230102472A AR P230102472 A ARP230102472 A AR P230102472A AR 130506 A1 AR130506 A1 AR 130506A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- antibodies
- human lair1
- human
- lair1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Transplantation (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente descripción se relaciona con anticuerpos que se unen a LAIR1 humano (anticuerpos anti-LAIR1 humano o anticuerpos anti-LAIR1 humano), composiciones que comprenden dichos anticuerpos anti-LAIR1 humano y métodos para usar dichos anticuerpos anti-LAIR1 humano. Reivindicación 1: Un anticuerpo que se une a LAIR1 humano, en donde el anticuerpo comprende una región variable de cadena pesada (VH) y una región variable de cadena ligera (VL), en donde la VH comprende regiones determinantes de complementariedad de la cadena pesada HCDR1, HCDR2, y HCDR3, y la VL comprende regiones determinantes de complementariedad de la cadena ligera LCDR1, LCDR2, y LCDR3, en donde HCDR1 comprende la sec. con núm. de ident.: 1, HCDR2 comprende la sec. con núm. de ident.: 2, HCDR3 comprende la sec. con núm. de ident.: 3, LCDR1 comprende la sec. con núm. de ident.: 4, LCDR2 comprende la sec. con núm. de ident.: 5, y LCDR3 comprende la sec. con núm. de ident.: 6. Reivindicación 17: Un ácido nucleico que comprende una secuencia que codifica la sec. con núm. de ident.: 9, 25, 10, 21, 27 o 22. Reivindicación 18: Un vector que comprende el ácido nucleico de la reivindicación 17. Reivindicación 27: Un proceso para producir un anticuerpo que comprende cultivar la célula de una cualquiera de las reivindicaciones 23 a 26 en condiciones tales que se exprese el anticuerpo y recuperar el anticuerpo expresado del medio de cultivo. Reivindicación 28: Un anticuerpo producido mediante el proceso de la reivindicación 27. Reivindicación 29: Una composición farmacéutica que comprende el anticuerpo de una cualquiera de las reivindicaciones 1 a 16 o 28, y un excipiente, diluyente o portador farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263375936P | 2022-09-16 | 2022-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR130506A1 true AR130506A1 (es) | 2024-12-11 |
Family
ID=90275943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230102472A AR130506A1 (es) | 2022-09-16 | 2023-09-15 | Anticuerpos anti-lair1 humano |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240101670A1 (es) |
| EP (1) | EP4587475A2 (es) |
| JP (1) | JP2025532639A (es) |
| KR (1) | KR20250080868A (es) |
| CN (1) | CN120202223A (es) |
| AR (1) | AR130506A1 (es) |
| AU (1) | AU2023342134A1 (es) |
| CA (1) | CA3267700A1 (es) |
| CL (1) | CL2025000695A1 (es) |
| CO (1) | CO2025003205A2 (es) |
| CR (1) | CR20250130A (es) |
| DO (1) | DOP2025000059A (es) |
| IL (1) | IL319594A (es) |
| MX (1) | MX2025003065A (es) |
| PE (1) | PE20251693A1 (es) |
| TW (1) | TW202426500A (es) |
| WO (1) | WO2024059789A2 (es) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018204986B2 (en) * | 2017-01-02 | 2024-08-01 | The Board Of Regents Of The University Of Texas System | Anti-LAIR1 antibodies and their uses |
-
2023
- 2023-09-15 CR CR20250130A patent/CR20250130A/es unknown
- 2023-09-15 AU AU2023342134A patent/AU2023342134A1/en active Pending
- 2023-09-15 PE PE2025000567A patent/PE20251693A1/es unknown
- 2023-09-15 CN CN202380079533.0A patent/CN120202223A/zh active Pending
- 2023-09-15 JP JP2025516228A patent/JP2025532639A/ja active Pending
- 2023-09-15 WO PCT/US2023/074294 patent/WO2024059789A2/en not_active Ceased
- 2023-09-15 US US18/467,957 patent/US20240101670A1/en active Pending
- 2023-09-15 TW TW112135399A patent/TW202426500A/zh unknown
- 2023-09-15 CA CA3267700A patent/CA3267700A1/en active Pending
- 2023-09-15 EP EP23793164.7A patent/EP4587475A2/en active Pending
- 2023-09-15 IL IL319594A patent/IL319594A/en unknown
- 2023-09-15 KR KR1020257012387A patent/KR20250080868A/ko active Pending
- 2023-09-15 AR ARP230102472A patent/AR130506A1/es unknown
-
2025
- 2025-03-12 DO DO2025000059A patent/DOP2025000059A/es unknown
- 2025-03-12 CL CL2025000695A patent/CL2025000695A1/es unknown
- 2025-03-12 CO CONC2025/0003205A patent/CO2025003205A2/es unknown
- 2025-03-14 MX MX2025003065A patent/MX2025003065A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2025000695A1 (es) | 2025-07-04 |
| US20240101670A1 (en) | 2024-03-28 |
| CR20250130A (es) | 2025-07-01 |
| WO2024059789A2 (en) | 2024-03-21 |
| MX2025003065A (es) | 2025-08-01 |
| IL319594A (en) | 2025-05-01 |
| CO2025003205A2 (es) | 2025-06-06 |
| EP4587475A2 (en) | 2025-07-23 |
| DOP2025000059A (es) | 2025-06-30 |
| AU2023342134A1 (en) | 2025-04-03 |
| WO2024059789A3 (en) | 2024-05-16 |
| KR20250080868A (ko) | 2025-06-05 |
| TW202426500A (zh) | 2024-07-01 |
| PE20251693A1 (es) | 2025-07-02 |
| JP2025532639A (ja) | 2025-10-01 |
| CA3267700A1 (en) | 2024-03-21 |
| CN120202223A (zh) | 2025-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024109678A5 (es) | ||
| AR100573A1 (es) | Anticuerpos anti-il-17, un método para producirlos y utilizarlos | |
| AR123083A1 (es) | Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos | |
| IL273841B1 (en) | Antibodies targeting cd137 and methods of use thereof | |
| AR125212A1 (es) | Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas | |
| AR123480A1 (es) | Moléculas de unión terapéuticas | |
| PE20240086A1 (es) | Anticuerpos anti-cd122 y usos de estos | |
| AR129935A1 (es) | Anticuerpo, enlazadores, carga activa, conjugados y aplicaciones de los mismos | |
| RU2014127287A (ru) | Антитела, используемые для пассивной вакцинации против гриппа | |
| JP2025067915A5 (es) | ||
| AR129991A1 (es) | Anticuerpos que se unen a la pad4 humana y usos de los mismos | |
| CL2024002975A1 (es) | Anticuerpo biespecífico anti-tigit y anti-pvrig, composición farmacéutica del mismo, y uso del mismo | |
| PE20230682A1 (es) | Anticuerpo anti-ox40 y usos del mismo | |
| AR110967A1 (es) | Anticuerpos miméticos fgf21 y su uso | |
| IL278323B2 (en) | Antibodies directed against glycoprotein IV | |
| AR130506A1 (es) | Anticuerpos anti-lair1 humano | |
| PE20240809A1 (es) | Composiciones y metodos de los anticuerpos anti-pacap | |
| AR125074A1 (es) | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso | |
| AR124917A1 (es) | Moléculas de unión a vegfa | |
| AR131528A1 (es) | Anticuerpos anti-b7h3 y métodos de uso | |
| AR133492A1 (es) | Agentes de unión a enpp3 y cd3 y métodos de uso de estos | |
| AR127056A1 (es) | Anticuerpos de transportador monocarboxilato humano 1 y usos de estos | |
| AR127270A1 (es) | Formulación de anticuerpos anti-cd47 | |
| AR132043A1 (es) | Anticuerpos muc1 y métodos de uso | |
| AR132159A1 (es) | Anticuerpos anti-b7h3 y métodos de uso |